Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Jean‐Baptiste Bachet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4337-286X; OpenAlex author ID A5061710022. Sources: ClinicalTrials.gov.

Their work

Papers
96 (first author 11, last author 17)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
231
Papers, trials and grants by year

2011: 3 papers · 2012: 5 papers · 2013: 3 papers · 2014: none · 2015: 8 papers · 2016: 6 papers · 2017: 4 papers · 2018: 4 papers · 2019: 6 papers · 2020: 7 papers, 1 trial · 2021: 10 papers · 2022: 8 papers · 2023: 5 papers · 2024: 11 papers · 2025: 7 papers · 2026: 9 papers

Papers 50 of 96

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Last author DOI 10.1016/j.canlet.2026.218745↗
  2. €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. Last author DOI 10.1016/j.clinre.2026.102873↗
  3. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Co-author DOI 10.1016/j.dld.2026.10.006↗
  4. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Last author DOI 10.1016/j.eclinm.2026.103998↗
  5. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Co-author DOI 10.1038/s41416-025-03274-0↗
  6. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  7. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  8. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  9. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  10. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  11. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. First author DOI 10.1016/j.ctrv.2025.102973↗
  12. Causes, management, and prognosis of severe gastrointestinal bleedings in critically ill patients with pancreatic cancer: A retrospective multicenter study. Co-author DOI 10.1016/j.dld.2024.08.041↗
  13. Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma. Last author DOI 10.1038/s41598-025-13160-7↗
  14. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  15. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… First author DOI 10.1200/jco-24-01378↗
  16. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  17. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  18. Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study from the French administrative database. Last author DOI 10.1016/j.clinre.2024.102426↗
  19. Clinical features and outcomes of patients with pancreatic cancer requiring unplanned medical ICU admission: A retrospective multicenter study. Co-author DOI 10.1016/j.dld.2023.08.049↗
  20. Should liver metastases of pancreatic adenocarcinoma be resected? Co-author DOI 10.1016/j.jviscsurg.2023.12.006↗
  21. Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.10.028↗
  22. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  23. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  24. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial. Co-author DOI 10.1097/sla.0000000000006468↗
  25. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Co-author DOI 10.1101/2024.04.30.591890↗
  26. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… First author DOI 10.1200/jco.22.02668↗
  27. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  28. Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. Last author DOI 10.1016/j.clinre.2023.102108↗
  29. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41467-023-39026-y↗
  30. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  31. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  32. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Last author DOI 10.21037/jgo-22-946↗
  33. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  34. BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2022.101880↗
  35. Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma? Last author DOI 10.1016/j.dld.2022.01.126↗
  36. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  37. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
  38. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1093/oncolo/oyac055↗
  39. PACpAInt: a deep learning approach to identify molecular subtypes of pancreatic adenocarcinoma on histology slides Co-author DOI 10.1101/2022.01.04.474951↗
  40. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Co-author DOI 10.1177/17588359221118019↗
  41. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  42. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  43. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Last author DOI 10.1016/j.clinre.2020.08.016↗
  44. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2021.01.042↗
  45. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  46. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. Last author DOI 10.1158/1078-0432.ccr-21-1907↗
  47. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  48. The role of radiotherapy in locally advanced pancreatic cancer. Last author DOI 10.1259/bjr.20210044↗
  49. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  50. Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcom… Co-author DOI 10.3390/ijms22136756↗

Trials 1

  1. FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX Principal investigator NCT04167007↗

Closest collaborators

The 25 strongest of 231 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 32 shared papers, 2013–2026 · strength 3.98
  2. Pascal R. Hammel · 34 shared papers, 2012–2026 · strength 3.46
  3. Rémy Nicolle · 19 shared papers, 2019–2026 · strength 2.94
  4. Léo Mas · 10 shared papers, 2020–2026 · strength 2.01
  5. Julien Taı̈eb · 18 shared papers, 2011–2026 · strength 1.83
  6. Magali Svrcek · 20 shared papers, 2012–2024 · strength 1.78
  7. Daniel Pietrasz · 16 shared papers, 2015–2025 · strength 1.61
  8. Nelson Dusetti · 11 shared papers, 2016–2026 · strength 1.61
  9. Pierre Laurent‐Puig · 12 shared papers, 2017–2026 · strength 1.61
  10. Vinciane Rebours · 10 shared papers, 2021–2026 · strength 1.56
  11. Anthony Turpin · 9 shared papers, 2020–2026 · strength 1.56
  12. Olivier Bouché · 12 shared papers, 2011–2026 · strength 1.54
  13. Jean‐Luc Van Laethem · 18 shared papers, 2011–2026 · strength 1.51
  14. Louis de Mestier · 11 shared papers, 2015–2026 · strength 1.49
  15. Juan Iovanna · 12 shared papers, 2012–2026 · strength 1.41
  16. Cindy Neuzillet · 9 shared papers, 2015–2026 · strength 1.34
  17. Nicolas Williet · 8 shared papers, 2018–2026 · strength 1.24
  18. Isabelle Trouilloud · 10 shared papers, 2011–2026 · strength 1.22
  19. Shulin Zhao · 7 shared papers, 2020–2026 · strength 1.11
  20. Laëtitia Dahan · 9 shared papers, 2015–2026 · strength 1.10
  21. Aurélien Lambert · 6 shared papers, 2016–2026 · strength 1.02
  22. Thierry Conroy · 9 shared papers, 2011–2026 · strength 0.96
  23. António Sá Cunha · 10 shared papers, 2015–2024 · strength 0.96
  24. Olivier Caliez · 5 shared papers, 2021–2025 · strength 0.94
  25. Déwi Vernerey · 5 shared papers, 2018–2026 · strength 0.90

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.